nature research

Corresponding author(s):	Rafael de Cabo
Last updated by author(s):	2021/09/18

Reporting Summary

Nature Research wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Research policies, see our Editorial Policies and the Editorial Policy Checklist.

~					
5	tа	ŤΙ	101	h	2

For	all statistical analyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.
n/a	Confirmed
	The exact sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement
	A statement on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.
	🗶 A description of all covariates tested
	🗶 A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons
	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient) AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)
	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>
×	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings
X	For hierarchical and complex designs, identification of the appropriate level for tests and full reporting of outcomes
×	Estimates of effect sizes (e.g. Cohen's <i>d</i> , Pearson's <i>r</i>), indicating how they were calculated
	Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.
So	ftware and code
Poli	cy information about <u>availability of computer code</u>
Da	ata collection Cytoflex platform for flow cytometry

For manuscripts utilizing custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and reviewers. We strongly encourage code deposition in a community repository (e.g. GitHub). See the Nature Research guidelines for submitting code & software for further information.

GraphPad Prism v. 8.4.2., CytoExpert v. 2.3, FlowJo v. 10.8, QuPath v. 0.2.2., and HOMA2 calculator v. 2.2.2. were used to analyze the data

Data

Data analysis

Policy information about availability of data

All manuscripts must include a data availability statement. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets

Cytoflex platform for flow cytometry

presented in the study.

- A list of figures that have associated raw data
- A description of any restrictions on data availability

Resources, reagents and microscopy images are available from the corresponding author, Rafael de Cabo (decabora@mail.nih.gov), upon reasonable request. Data generated in this study are provided in the Supplementary Information/Source Data file.

Field-specific reporting
Please select the one below that is the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences Behavioural & social sciences Ecological, evolutionary & environmental sciences
For a reference copy of the document with all sections, see nature.com/documents/nr-reporting-summary-flat.pdf
Life sciences study design
All studies must disclose on these points even when the disclosure is negative.
No statistical methods were used to predetermine sample size; however, one of our recent publications has highlighted the importance of proper sample size estimation in order to ensure adequate power to detect significant group differences or treatment effects in physiological and metabolic outcomes while controlling the type I error rate (PMID: 34407413). Using these estimates, we employed a sample size sufficient to achieve adequate power.
Data exclusions No data were excluded from the analysis.
Replication All experiments were reproduced at least twice to reliably support conclusions stated in the manuscript.
Randomization Mice were randomly divided into experimental groups and fed either a standard laboratory chow or subjected to a dietary intervention [calorie restriction, a plant-based diet (FMD), 4:10 feeding cycles]. No significant differences in body weight were observed at baseline.
The investigators were blinded to group allocation during scoring of lung metastases, tumor sizing and mitotic activity, recording of body weight and food consumption, flow cytometry, biochemical markers, and organ weights.
Reporting for specific materials, systems and methods
We require information from authors about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material system or method listed is relevant to your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
Materials & experimental systems Methods
n/a Involved in the study n/a Involved in the study
Antibodies
■ Image: Line state of the
Palaeontology and archaeology MRI-based neuroimaging
X Animals and other organisms
Human research participants Clinical data

Antibodies

Antibodies used

Dual use research of concern

Serum insulin was measured using a mouse ultra-sensitive enzyme-linked immunosorbent assay (Catalog #90080; Crystal Chem, Downers Grove, IL). The source of antibodies used for flow cytometry were the following: CD4 BV605 (Biolegend, Catalog #100451); CD8a BUV395 (BD Biosciences Catalog #: 563786); FoxP3 PE (Invitrogen/eBioscience, Catalog #12-5773-82); CD11b BV785 (Biolegend, Catalog #101243) and CD11b BUV661 (BD Biosciences, Catalog #612977); Gr1 PB (Biolegend, Catalog # 108430) and Gr1 BV421 (BD Biosciences, Catalog # 562709); Ly6G PerCP Cy5.5 (BD Biosciences, Catalog #560602); Ly6C BV510 (Biolegend, Catalog #128033); CD103 PE/Dazzle c594 (Biolegend, Catalog #121430); CD163 PE Cy7 (Invitrogen/eBioscience Catalog #25-1631-82); F4/80 APC (Biolegend, Catalog #123116); Granzyme B PE (Invitrogen/eBioscience, Catalog #12-8898-82); Viability Dye eFluor780 (Invitrogen/eBioscience, Catalog #65-0865-18).

Validation

We relied on the validation statements on the manufacturer's website for each antibody.

Eukaryotic cell lines

Policy information about cell lines

Cell line source(s)

4T1 cells were purchased from American Type Culture Collection (ATCC) #CRL-2539.

Authentication

We did not independently authenticate this cell line.

Mycoplasma contamination

These cells tested negative for mycoplasma contamination.

Commonly misidentified lines (See ICLAC register)

No commonly misidentified cell lines were used in this study.

Animals and other organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research

12- and 36-week-old BALB/6J female mice were procured from the Jackson Laboratory (Bar Harbor, ME). Laboratory animals

Wild animals No wild animals were used in the study.

Field-collected samples No field collected samples were used in the study.

Animal protocols were approved by the Animal Care and Use Committee (277-TGB-2024) of the National Institute on Aging, National Ethics oversight

Institutes of Health.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- | All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation The sample preparation is described in the method section of the manuscript.

Cytoflex platform, Beckman Coulter, Cytoflex-LX Instrument

Software CytoExpert v. 2.3, FlowJo v. 10.8

Cell population abundance These parameters are the topic of the current paper and are provided as data in the main-text figures and Supplemental

figures.

Gating strategy Supplemental Figures 8m and 11j provide the gating strategy. Moreover, the method section offers additional information

with regard to the gating strategy.

x Tick this box to confirm that a figure exemplifying the gating strategy is provided in the Supplementary Information.